

# Index

- 4 Gs of drug innovation 41, 70  
23andMe 17–18, 163
- A *see* adenine
- accelerated development review, FDA  
82
- accommodation design 210
- Acorda Therapeutics 256, 287
- ACE inhibitors 46–7
- acne 153–5
- ADD *see* Attention Deficit Disorder
- addiction therapies 151
- adenine (A) 27–8, 35
- adenosine triphosphate (ATP) 29, 33–4
- adult stem cells 166, 168
- Afreeza (diabetes drug) 126–7
- ageing 158–62, 240–4
- “ageing” genes 89
- ageing populations 181–8
- China 199–200
  - investment 214–15
  - Japan 185–6
  - life expectancy 181–8
  - monitor robots 223–8
  - over 60s 184–8, 199–200
  - over 80s 185–6
  - psychological outlook 195–6
  - retail goods/services 212–13
  - social impact 195–6
  - youth shortages 218
- AI *see* artificial intelligence
- airbags 233
- airline industry 69
- alcohol abuse 151
- Aldebaran Robotics 226–7
- Alexion 149
- Allergan 249, 265, 283
- allotropes 233
- ALN-VSP (cancer drug) 261
- Alynham Pharmaceuticals 176, 256, 261, 288
- Alzheimer’s disease 132–6
- APOE gene 160
  - Aricept 88, 135
  - FDA approval 82–3
  - new drugs 135
  - robotic pets 229, 231
- America Invents Act 2011 78
- Amgen 60–61, 69, 256–7, 288
- Denosumab 143, 257
  - FTO principle 78
  - oncolytic poxviruses 100
  - Xgeva 156, 257
- AmphiPhi Biosciences 113, 256, 279, 294
- Amylin Pharmaceuticals 122, 256, 288
- anabolism 34
- angina 45–6, 47, 131
- angiogenesis inhibitors 94–5
- animals 72
- Antabloc (RA drug) 276
- Anthera Pharmaceuticals 256, 294
- anti-ageing medicine 243
- antibiotics 43–4, 107–18
- anti-cancer agents 48–50, 98–100
- anticholinergic drugs 145
- anti-depressants 42
- antifungal drugs 109
- anti-histamines 42–3, 47
- anti-psychotic drugs 41–2, 150
- antiretroviral drugs 115
- antisense therapies 177–8, 256
- antiviral drugs 109
- apolipoprotein E (APOE) gene  
159–60
- APP *see* beta-selective APP Cleaving  
Enzyme
- Aricept (Alzheimer drug) 88, 135

- Arrowhead Research
  - company overview 295
  - as investment choice 256, 279
  - Nanotype 179–80
  - obesity 123–4, 127
  - siRNA 176–7
- arsenical compounds 41
- arthritis 48, 50, 139–43
- artificial intelligence (AI) 5, 9–12
- Asimo robot 224–5, 309
- Asimov, Isaac 232
- assisted living communities 210
- Astellas Pharma 249, 267–8, 283
- asthma 143–5
- AstraZeneca 250, 261
- atherosclerosis 159–60
- atoms 24–35
- ATP *see* adenine triphosphate
- Attention Deficit Disorder (ADD) 263
- attitude management 244
- Avastin (cancer drug) 253
- AVI BioPharma 295
- Azilect (Parkinson's drug) 139
  
- BACE *see* beta-selective APP Cleaving Enzyme
- bacterial infections 109–10
- Bafetinib (leukaemia drug) 277
- balanced biopharma portfolio 280–1
- Basilea Pharmaceutica 295
- Bayh–Dole Act 1980, US 71
- BCG vaccine 117
- Benlysta (lupus drug) 141
- beta blockers 46–7
- beta-interferon (MS treatment) 137
- beta-selective APP Cleaving Enzyme (BACE) 136
- big pharma
  - acquiring biotech firms 62–4
  - and biopharma 58–73, 85
  - developing world 251
  - growth 253
  - investment 248–56
  - key financial charts 325–6
  - notable companies 59
  - reorganization 55–6
  - see also individual companies;*
  - pharmaceutical industry
- Biogen Idec 137–8, 256, 257–8, 289
- bioinformatics 71, 165
- biological networks 33–4
- biologicals *see* biopharma
- biologics 59, 62, 73, 85
- biology and technology 1, 8, 13–21
  - convergence of 1, 13–21
  - genetic self-knowledge 16–18
  - personalized medicine 16, 20
  - synthetic biology 14–16
  - tailor-made body parts 18–21
- biomedical devices 223
- Biondva Pharmaceuticals 295
- biopharma 23, 51–4, 247–304, 307
  - balanced portfolio 280–1
  - and big pharma 59–72
  - business models 65
  - company overviews 282–304
  - conservative portfolio 279–80
  - failures/successes 65
  - favoured stocks 249
  - investment 70, 247–304
  - speculative portfolio 281–2
  - startups 70–1
  - top drugs 62
  - see also individual companies;*
  - pharmaceutical industry
- bio-printers 21
- bio-rubber 21
- bioscience 205–18
  - disruptions 205–18
  - food industry 213–14
  - geopolitics 211–12
  - healthcare 206–10
  - influence of 205–18
  - insurance 206–10
  - investment 214–15
  - the law 215–17
  - politics 211
  - real estate 210
  - retail goods/services 212–13
  - youth shortages 217–18
- BioTime 179, 256, 278–9, 296
- Black, James 47
- bladders 179
- Blagosklonny, Mikhail V. 238
- blood tests 243
- BMI *see* Body Mass Index
- Boceprevir (hepatitis drug) 113
- Body Mass Index (BMI) 236–7
- body parts 18–21
- bone disease 153–6
- Botox 265
- Boyer, Herbert 60

- Brazil 251  
 Buettner, Dan 239  
 Business Insights research firm 96–7  
 Byetta (diabetes drug) 122
- C *see* cytosine
- Calment, Jeanne 182  
 calorie-restricted diets 161, 237–8  
 cancer 89–107  
   angiogenesis inhibitors 94–5  
   anti-cancer agents 48–50, 98–100  
   causal links 91  
   China 66–7  
   common types 90  
   companies to watch 104–6  
   early detection 91  
   epigenetic drugs 95–7  
   Epizyme's approach 65  
   FDA drug approval 80, 81, 83, 92–3  
   gene knockout 98–9  
   gene patents 74  
   Harvard Mouse 74  
   immortality 158–9  
   key drug sectors 93  
   kinase inhibitors 102–4  
   microchips 13  
   pain relief 152–3  
   PARP inhibitors 102–4  
   pathway blockers 101–2  
   promising prospects 106–7  
   relapses 92  
   targeted therapies 93–104  
 carbohydrates 25  
 carbon nanotubes 233–4  
 CardioFocus 303  
 cardiovascular disease 45–7, 88, 128–32, 170  
 catabolism 34  
 CDAD *see* *Clostridium difficile* associated diarrhoea  
 Celgene 63–4, 256, 258, 289  
 cell culture 167  
 cell fusion 53  
 Cellceutix 256, 272, 296  
 cells 24–35, 53, 167  
 cellular biology 169  
 Cellular Dynamics 168–9, 303  
*Central Dogma of Molecular Biology* 31  
 central nervous system (CNS) 150–3  
 Charles River Laboratories 72
- China  
   biopharma 251  
   cancer 67  
   demographic changes 188, 190–3, 196, 198–200  
   fertility rates 190–3  
   geopolitical concerns 211–12  
   labour pool 192  
   one-child policy 199  
   over 60s 199–200  
   world labour pool 192–3  
 chlorpromazine 42  
 cholesterol 46, 128–31, 249  
 chromosomes 28–31  
   *see also* telomeres  
 chronic kidney disease (CKD) 88, 123, 127  
 Cisco Systems 5–6  
 CKD *see* chronic kidney disease  
 Claritin (anti-histamine) 42–3  
 cloning 18–19, 53  
*Clostridium (C.) difficile* 110–12  
*Clostridium difficile* associated diarrhoea (CDAD) 274  
 CNS *see* central nervous system  
 combinatorial chemistry 71  
 combinatorial probe-anchor ligation (cPAL) 164–5  
 companion diagnostics 255  
 company-based schools 218  
 Complete Genomics 163–5  
 computers  
   *Deep Blue* 9  
   processing power 221–2, 310  
   quantum 4–5  
   *Watson* 9–12  
 congenital diseases 207–8  
 consciousness 12  
 conservative biopharma portfolio 279–80  
 contraceptive pill 47–8  
 Contract Research Organizations (CROs) 81  
 COPD respiratory disease 144–5  
 Cortisone 48  
 COX inhibitors 50  
 cPAL *see* combinatorial probe-anchor ligation  
 Crestor (statin) 130  
 Crick, Francis 27  
 CROs *see* Contract Research Organizations

- Cubist Pharmaceuticals 256, 274, 289
- Curagen 96
- curing diseases 87–156, 307
- Curis 97, 296
- cybernetics 7
- cyborgs 7–8
- cytosine (C) 27–8, 35
- cytotoxic drugs 93
- CytRx 256, 277–8
  
- da Vinci Surgical System 220–1
- death 158–9
- Deep Blue* IBM computer 9
- dementia *see* Alzheimer's disease
- demographic changes 181–203, 308–9
  - ageing populations 181–8, 195–6, 199–200
  - declining populations 186
  - developed world 193–7
  - government action 193, 200–3
  - immigration 193–5
  - impact of ageing 195–6
  - Japan 185–6, 190–2, 194–5, 197–8
  - life expectancy 181–8
  - maximising workers 201
  - support ratios 197–8
  - sustainable policies 201–202
  - United States 190–1, 193, 196–7
  - world labour pool 191–3
- Dendreon 100
- Denosumab (osteoarthritis drug) 143, 257
- deoxyribonucleic acid *see* DNA
- depressive illnesses 150–1
- dermatology 153–6
- developing world 251
  - see also* China; India
- diabetes 124–8
  - China 66–7
  - disease pathways 32
  - gout 141–2
  - hormones 48
  - obesity 118–19, 122, 126–7
  - stem cells 170
- diarrhoea 274
- diet 161, 237–8, 241–2
- Difacid (CDAD drug) 274
- digitalis (cardiovascular drug) 45
- Dioscorides (Roman medic) 36, 49
- diseases
  - bone disease 153–6
  - breakthroughs 88
  - cardiovascular disease 45–7, 88, 128–32, 170
  - curing disease 87–156, 307
  - dermatology 153–6
  - gastrointestinal disease 153–6
  - infectious diseases 37–41, 107–18, 275
  - kidney disease 88, 118, 123, 127
  - major categories 57–8
  - neurodegeneration 132–43
  - ophthalmology 153–6
  - pain relief 150–3
  - rare diseases 146–9
  - respiratory disease 143–6
  - rheumatology 132–3, 139–43
  - therapeutic prospects 87–156
  - see also individual diseases*; obesity
- DMD *see* Duchenne Muscular Dystrophy
- DNA 23–32, 35
  - discovery of 26–32
  - gene patents 74–5
  - genetic self-knowledge 17
  - medical history 23–32
  - nucleic acids 25, 27
  - recombinant 52–3, 60–1
  - synthetic biology 14–15
  - ZFPs 175
  - see also* genomes
- DNA nanoballs (DNBs) 164–5
- domestic robots 228–9
- dopamine 132, 138
  - see also* Parkinson's disease
- double helix structure 23–4, 27–8
- DPP-IV inhibitors 125
- drug industry 55–86
  - drug development 71–86, 308
  - drug targets 72
  - FDA approval 58, 79–84, 92–3
  - financial outlay 56–7
  - model reinvention 55–86
  - patents 56, 73–9, 308
  - see also* pharmaceutical industry
- drugs
  - FDA definition 56
  - first true drugs 39
  - see also individual drugs*; medicine
- Duchenne Muscular Dystrophy (DMD) 148
- dyeing industry 39–40
- Dynavax Technologies 256, 272–3, 297

- Egyptian medicine 36  
 Ehrlich, Paul 40–1  
 electrophysiology (EP) 222  
 Eli Lilly 250  
 EMA *see* European Medical Agency  
 Embden–Mayerhof pathway 34  
 embryonic stem cells 166–7, 216  
 employer insurance 209  
 energy conservation 238  
 EP *see* electrophysiology  
 epidemics 37, 39, 109  
 epigenetic drugs 95–7  
 Epizyme 65  
*Escherichia Coli* (*E. Coli*) 111  
 ETFs *see* exchange-traded funds  
 ethics and robots 232  
 eukaryotic cells 28–9  
 European Medical Agency (EMA) 58, 78  
 Evans, Dave 5–6  
 exchange-traded funds (ETFs) 248  
 exercise 242  
  
*Facebook* 214  
 FDA *see* Food and Drug Administration  
 female life expectancy 182–3  
 fertility rates 187–91, 201–202, 217–18, 308  
 Fleming, Alexander 43  
 Food and Drug Administration (FDA), US 307  
   approval 58, 79–84, 92–3  
   budget 72  
   definition of “drug” 56  
   fast tracking drug 22  
   obesity 120  
 food industry 213–14  
 Forest Laboratories 256, 266, 290  
 Fostamatinib (RA drug) 261  
 four Gs of drug innovation 41, 70  
 France 193–4  
 free radicals 161  
 Freedom to Operate (FTO) principle 78  
 Friedman, Eby 4  
 FTO *see* Freedom to Operate principle  
 futurists 1–12, 305  
  
 G *see* guanine  
 Galen (Roman medic) 36  
 gastrointestinal disease 153–6  
 Gaucher’s disease 147–8  
 gene therapy 89, 157, 170–8  
   antisense therapies 177–8  
   germ line therapy 171–2  
   investment 255  
   nanoparticles 173–4  
   retroviral vectors 172–3  
   somatic therapy 171–2  
   ZFPTs 174–5  
 Genentech 256  
   angiogenesis inhibitors 94–5  
   first biopharma company 59–60  
   gene patents 75  
   success 69  
   VCs 67–8  
 genes  
   “ageing” genes 89  
   Alzheimer’s disease 133–5  
   APOE 159–60  
   disease pathways 32–3  
   DNA 29–33  
   gene knockout 98–9  
   life expectancy 239  
   patents 74–6  
   TP53 104  
   *see also* gene ...; Human Genome Project  
   genetic engineering 52  
   genetic self-knowledge 16–18  
   genetically-modified (GM) foods 214  
   genomes 14–17, 163–6  
     *see also* human genome ...  
   Genomic Health 297  
   genomics 157–80, 256  
   genotyping 17  
   Genzyme 260  
   geopolitics 211–12  
   germ line gene therapy 171–2  
   Germany 193  
   Gilead Sciences  
     business models 63–4, 66, 69  
     company overview 290  
     HIV/AIDS drugs 115  
     as investment choice 256, 259  
     Ranexa (drug) 131  
   GlaxoSmithKline (GSK) 108, 144–6, 249, 252, 284  
   Gleevec kinase inhibitor 102–3  
   GLP-1 (hormone) 125–6  
   glycolysis 34  
   GM *see* genetically-modified foods  
   gout 34, 141–2  
   government action 193, 200–3

- government bonds 215
- Gram-negative infections 111–12
- Greek medicine 36
- GSK *see* GlaxoSmithKline
- Guangdong Province, China 200
- guanine (G) 27–8, 35
  
- Hansen Medical 222, 297
- Harvard Mouse 73
- Hayflick Limit 160
- health 305, 309
  - see also* lifestyle
- healthcare 206–10
  - demographic changes 193, 195, 198, 200
  - insurance 206–10
  - lifestyle choices 208–9
  - medical insurance 209
  - youth shortage 218
- heart disease *see* cardiovascular disease
- HeLa cells 158
- Heparin, (cardiovascular drug) 45
- hepatitis 107, 113–14, 272
- Hepislav (hepatitis vaccine) 272
- herbal remedies 37
- Herceptin (cancer drug) 53–4, 253, 255
- HGP *see* Human Genome Project
- high blood pressure 128–30
  - see also* hypertension
- high throughput screening (HTS) 35, 71
- hiPS *see* induced pluripotent human stem cells
- histamines 47
- HIV/AIDS 107, 114–16, 275
- HIVCide (HIV/AIDS drug) 275
- Honda 224–6, 290, 309
- hormones 33, 48, 161–2
- housemaid robots 228–9
- HPV *see* Human Papilloma Virus
- HTS *see* high throughput screening
- human cells 29–30
- Human Genome Project (HGP) 30–1, 35, 71, 311
- human genome sequencing 15–17, 310–11
  - drug industry 70–1
  - insurance 206–8
  - the law 216–17
- Human Papilloma Virus (HPV) 117–18
- Hung, David 105
- Hunter Syndrome 149
- hydrogels 179
- hypercholesterolemia 131
- hyperplasia 24–5
- hypertension 47, 129–31, 145
- hypertrophy 25
  
- IBM 4, 9–10
- IBS (irritable bowel syndrome) 154
- immigration 193–5
- immortality 158–9
- ImmunoGen 104
- immunosuppressants 48
- immunotherapeutics 99
- implants 7–8
- India
  - biopharma 251
  - demographic changes 189–93, 196
  - fertility rates 189–91
  - geopolitical concerns 211–12
  - labour pool 192
- induced pluripotent human stem cells (hiPS) 163–9
- infectious diseases 37–41, 107–18
  - epidemics 109
  - hepatitis 107, 113–14
  - HIV/AIDS 107, 114–16, 275
  - malaria 116–7
  - new antibiotics 107–18
  - tuberculosis 117
  - vaccines 116, 117–18
  - worldwide mortality 108
- Infinity Pharmaceuticals 273, 297
- influenza 118
- innovation, four Gs 41, 70
- insulin 48, 53, 124–7
  - see also* diabetes
- insurance 206–10
  - employer insurance 209
  - genome sequencing 206–8
  - healthcare 206–10
  - lifestyle choices 208–9
  - pooled insurance 208
- Intel 2, 4
- Intuitive Surgical 221, 298
- investment 214–15, 247–302
- iRobot 228–9, 298
- irritable bowel syndrome (IBS) 154
- Isis Pharmaceuticals 178, 256, 260, 191
  
- Japan 308–9
  - ageing populations 185–6
  - fertility rates 188, 190–1

- immigration 194–5
- labour pool 192
- monitor robots 224–8
- support ratios 197–8
- “Jasmine Revolution” 216
- Jenner, Edward 37
- Johnson & Johnson 250, 284
  
- Kekich, Dave 240
- Keryx Biopharmaceuticals 298
- Kessler, Andy 13
- Kevetrin (cancer drug) 272
- kidney disease 88, 118, 122–3, 127
- kinase inhibitors 95, 102–4
- Krystexxa (gout drug) 142
- Kurzweil, Ray 2 5, 6
  
- labour pool, world 191–5
- Lasik eye surgery system 221
- the law 215–17
- Leonardo 174, 176
- Levodopa (Parkinson’s drug) 138–9
- life expectancy 158–62, 181–8
  - lifestyle 237–40
  - longevity traits 238–40
  - nine secrets 239–40
- lifestyle 235–45, 309
  - choices and insurance 208–9
  - cure to ageing 240–4
  - extending life 237–8
  - longevity traits 238–40
  - maintenance 235–45, 309
  - obesity 235–7
  - telomeres 244–5
- Lilly 250
- Linacotide (gastrointestinal drug) 154
- lipids 25–6, 46
- Lipitor (cardiovascular drug) 129–30, 249
- liposomes 174
- Lister, Joseph 39, 51
- longevity 238–40, 311–12
- LSDs *see* lysosomal storage disorders
- lupus 140–1
- lysosomal storage disorders (LSDs) 147
  
- MAbs *see* monoclonal antibodies
- Macchiarini, Paolo 20
- magic bullets 41
- MAKO Surgical 222, 299
- malaria 116–7
- male life expectancy 182–3
- managed funds 248
- Manhattan Beach Project 240
- Mannkind 126–7, 299
- MAP 256
- MDV3100 drug 105–6
- medical devices 84
- medical insurance 254
- medical knowledge 182
- medicine 23–54, 306–7
  - atoms and cells 24–35
  - DNA 23–32
  - evolution of 23–54, 306–7
  - personalized 16, 20
  - pharmaceutical industry 36–54
  - precision 16, 93–4
  - targeted 93–104
- Medicis Pharmaceutical 256, 264–5, 291
- Medivation 104–6, 256, 267, 291
- meiosis 30
- Mendelian diseases 32
- Merck & Co. 249, 251, 285
- Merrimack Pharmaceuticals 106, 291
- messenger RNA (mRNA) 30–1, 53, 177–8
- metabolism 33–4
- Methylgene 299
- micro RNA (miRNA) 173, 176
- microchips 13
- migraine 152
- migration to warm climate 210
- military robots
- Mipomersen (cholesterol drug) 260
- miRNA *see* micro RNA
- mitochondria 29
- mobile phones 311
- molecules 24–5
- monitor robots 223–8
  - Asimo* 224–5, 309
  - Japan 224–8
  - Nao* 226–7
  - nurse robots 223–8
  - Stride Management Assist Device 225–6
- monoclonal antibodies (MAbs) 53–4, 60–1, 70
- Moore, Gordon 2–3
- Moore’s Law 2–4, 9, 10, 219, 305, 310
- Morphine 39
- mRNA *see* messenger RNA
- MRSA 110, 112, 118
- multiple sclerosis (MS) 132–3, 136–8

- muscular dystrophy 148
- mutations 32
  
- nanotechnology 14, 219, 232–4
  - allotropes 233
  - nano medicine 170, 173–4
  - nano-robots 223
  - nanotubes 233–4
- Nanotype 179–80
- NanoViricides 115–16, 256, 275, 299
- Nao* robot 226–7
- National Cancer Institute (NCI), US 92
- Navidea Biopharmaceuticals 299
- NDM-1 pathogen 111
- Nektar Therapeutics 256, 271, 292
- Neuralstem 300
- neurodegeneration 83, 132–43
- NicOx 300
- non-steroidal anti-inflammatory drugs (NSAIDs) 50
- notch pathway 101
- Nova Nordisk 285
- Novartis 249, 252, 285
- Novelos Therapeutics 300
- NSAIDs *see* non-steroidal anti-inflammatory drugs
- nuclei 24
- nucleic acids 25, 27
  - see also* DNA
- nurse robots 223–8
  
- obesity 118–27
  - BMI 236–7
  - diabetes 118–19, 122, 126–7
  - FDA approval 120
  - kidney disease 123
  - lifestyle 235–7
  - weight-loss drugs 119–23
- OECD countries 197–8
- oncolytic poxviruses 98–100
- one-child policy, China 199
- Onyx 256
- ophthalmology 153–6
- Opium 39
- Optimer Pharmaceuticals 256, 274, 292
- Orexigen Therapeutics 301
- organ growth 178–80
- organic nitrates 45
- Orlistat (obesity drug) 120
- orphan diseases 82, 146–9, 256
- osteoarthritis 142–3
- osteoporosis 155
  
- Ott, Harold 19–20
- overseas citizens 201–202
- Oxycontin (pain drug) 152
  
- P13K/AKT/mTOR pathway 101–2
- p53 pathway 104
- Pacific Biosciences 165–6, 256
- Pacific Yew tree 49
- pain relief 150–3
- parasitic infections 40–1
- paroxysmal nocturnal hemoglobinuria (PNH) 149
- Parkinson's disease 132–3, 138–9, 172
- Paro* robotic pet 230–1
- PARP inhibitors 102–4
- partnerships 64, 81
- patents 73–9, 308
  - animals 74
  - expiry 56
  - genes 74–6
  - length of life 77
- pathways for disease 32–4, 101–4
- Pearl, Raymond 160
- PEG *see* polyethylene glycol
- penicillin 43–4
- pensions 187, 193, 200, 215
- Perkin, William 39–40
- personalized medicine 16, 20
- pets (robotic) 229–32
- Pfizer 135, 249, 251–3, 286
- phage therapy 112–13
- pharmaceutical industry 36–54
  - birth of modern medicine 37–51
  - early history 36–7
  - FDA approval failures 82–3
  - see also* big pharma; biopharma; drug industry
- Pharmacyclics 96, 301
- phones (mobile) 311
- Pleo* robotic pet 231–1
- Plethora Solutions Holdings 279, 301
- pluripotent stem cells 167–9
- PNH *see* paroxysmal nocturnal hemoglobinuria
- politics 211
- Poly ADP Ribose Polymerase *see* PARP
- polyethylene glycol (PEG) 54
- PolyMedix 112
- precision medicine 16, 93–4
- prediction of trends 312–13
- price of drugs 254
- price of food 213

- price-earnings ratios 250–1
- processing power of computers 221–2, 310
- profitless prosperity 69
- Prontosil (antibacterial drug) 41
- prostate cancer 105–6
- protein kinases 102
- proteins 25–6, 26, 40
- Prozac (SSRI) 42
- psoriasis 155
- pulmonary hypertension 145
- quantum computers 4–5
- quantum theory 162–3
- Quinine sulphate (malaria drug) 39, 307
- R&D *see* research and development
- RA *see* rheumatoid arthritis
- Ranexa (angina drug) 131
- rare diseases 146–9
- Rate of Living hypothesis 160
- rational drug design (RDD) 71
- rDNA *see* recombinant DNA
- real estate 210
- Reata Pharmaceuticals 123, 127, 304
- receptors 26, 40, 72
- recombinant DNA (rDNA) 52–3, 60–1
- regeneration 157, 178–80
- reproduction 161
- research and development (R&D) 252, 255
- respiratory disease 143–6
- retail goods/services 212–13
- retroviral vectors 172–4
- rheumatoid arthritis (RA) 49, 50, 139
- rheumatology 132–3, 139–43
- ribonucleic acid *see* RNA
- Rigel Pharmaceuticals 256, 261–2
- Rituxan (lymphoma drug) 253, 257
- RNA
  - DNA 26–7, 30–2, 52
  - gene therapy 175–7
  - miRNA 173, 176
  - mRNA 30–1, 53, 177–8
  - Pacific Biosciences 166
  - RNAi 121, 175–7
  - siRNAs 98, 173, 175–7, 256
  - see also* DNA
- RNA interference (RNAi) 121, 175–7
- robotics 219–34, 309
  - domestic assistance 228–9
  - ethics 232
  - monitors/nurses 223–8
  - pets 229–32
  - surgery 220–3
- Roche Holdings 249, 252, 253, 255–6, 286
- Roman medicine 36–7
- Russia 251
- salmonella 111
- Sangamo BioSciences 173, 301
- sanitation 39
- Sanofi 250–1, 287
- Savient Pharmaceuticals 256, 292
- scaffolds of organs 19–21
- schizophrenia 149–50
- serotonin reuptake inhibitors (SSRIs) 42
- sex cells 29–30
- Shire 256, 263–4, 293
- short interfering RNA strands (siRNAs) 98, 173, 175–7, 256
- signal transduction pathways 33
- singularity hypothesis 5–7, 306
- The Singularity is Near* (Kurzweil) 2
- Sinopharm Group 293
- siRNAs *see* short interfering RNA strands
- smallpox 37–8
- social impact of ageing population 195–6
- Soligenix 256, 302
- somatic cells 29
- somatic gene therapy 171–2
- sonic hedgehog pathway 100–1
- speculative biopharma portfolio 281–2
- SSRIs *see* serotonin reuptake inhibitors
- Star Scientific 256, 276–7, 302
- startup firms 70–1
- statins (cholesterol drugs) 46, 129–30
- stem cells 157, 166–70
  - embryonic 166–7, 216
  - investment 256
  - start of life 24
  - WARF 76–7
- stomach ulcers 47
- stress management 244
- Stride Management Assist Device 225–6
- Stryker 222, 293
- Summit 302
- superbugs 44
- superfoods 241
- supplements 242–3
- support ratios 197–8
- surgery 220–3
  - biomedical devices 223
  - da Vinci Surgical System 220–1
  - Hanson Medical 222

- Lasik eye procedure 220
  - Lister 39
  - MAKO 222
  - nano-robots 223
  - procedures 220–3
  - TOGA 122
  - tracheal 20
  - Swaziland 182
  - Synergy Pharmaceuticals 303
  - synthetic biology 14–16, 306
  - synthetic life forms 12
  - systemic lupus erythematosus 140–1
  - T *see* thymine
  - Tarceva (cancer drug) 95
  - targeted cancer therapies 93–104
  - tax 202–3, 254
  - Taxol (cancer drug) 49–50
  - technology *see* nanotechnology;  
transformational technologies
  - Telaprevir (hepatitis drug) 113, 262
  - telomerase 30, 160, 245
  - telomers 30–1, 160, 244–5
  - Teva Pharmaceutical Industries 137, 287
  - Thalidomide 50–1
  - Thomson, Jamie 77, 168
  - thought-controlled devices 8
  - three-dimensional bio-printers 21
  - thrombosis 131
  - thymine (T) 27–8, 35
  - TOGA *see* transoral gastroplasty
  - TP53 gene 104
  - tracheal surgery 20
  - transfection agents 173–4
  - transformational technologies 1–21, 305–6
    - AI 5, 9–12
    - biology and technology 13–21
    - consciousness 12
    - future aspects 1–12
    - synthetic biology 14–16, 306
  - transoral gastroplasty (TOGA) 122
  - trend predictions 312–13
  - Tri-Gate* transistor chips 4
  - Triptans (migraine drugs) 152
  - Trojantec 98, 101, 304
  - Trypan Red dye 41
  - tuberculosis 117
  - Turing test 9
  - Tysabri (MS drug) 257
  - unemployment 212
  - United States (US)
    - big pharma 254
    - demographic changes 190–1, 193, 196–7
    - drug industry 57, 66–8, 73, 77–8
    - geopolitical concerns 211–12
    - obesity 118–19
  - vaccines 116, 117–18
    - anti-cancer viruses 98–100
    - BCG 117
    - history of 37
    - HIV/AIDS 116
    - infectious diseases 116, 117–18
    - malaria 116–7
  - Valium 43
  - variation 37
  - VCs *see* venture capitalists
  - VEGF-Trap Eye (eye drug) 153
  - Ventnor, Craig 15
  - venture capitalists (VCs) 65, 67–8, 215
  - Vertex Pharmaceuticals 256, 262–3, 294
  - Viagra 55, 62
  - da Vinci Surgical System 220–1
  - Viread (HIV/AIDS drug) 259
  - viruses 98–100, 117–18
  - Vivus 303
  - WARF *see* Wisconsin Alumni Research Foundation
  - Warfarin (blood thinner) 16, 45, 76
  - Warwick, Kevin 7–8
  - Watson* IBM computer 9–12
  - Watson, James 27, 35
  - wealth 305
  - weight-loss drugs 119–23
  - WikiLeaks* 216–17
  - Wisconsin Alumni Research Foundation (WARF) 76–7
  - Xgeva (bone drug) 156
  - Yew trees 49
  - youth shortages 217–18
  - Zinc Finger Protein Transcription Factors (ZFPTs) 174–5
- Index compiled by Indexing Specialists (UK) Ltd*